Immunotherapy Continues to Shape Future Bladder Cancer Paradigm – OncLive
OncLive |
Immunotherapy Continues to Shape Future Bladder Cancer Paradigm
OncLive The second-line setting of bladder cancer has historically seen little progress prior to May 2016, the time which atezolizumab (Tecentriq) was approved by the FDA as a treatment for patients with locally advanced or metastatic disease that progressed … |
